Trial Profile
A multi-arm Phase IIa efficacy and safety study of Sutent® and Afinitor® refractory pancreatic NET patients as well as solid tumor patients
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Surufatinib (Primary) ; Everolimus
- Indications Neuroendocrine tumours; Pancreatic cancer; Solid tumours
- Focus Therapeutic Use
- 19 Mar 2018 New trial record